This AIM Rule 26 information was last updated on 9th May 2018.
Feedback plc is admitted to trading on the AIM market of the London Stock Exchange.
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. For more information please visit http://www.fbk.com/about/.
Dr Alastair Riddell, Executive Chairman
Dr Riddell has over 30 years’ experience in the pharmaceutical, life science and biotech industries, with 18 years as a main board director. After 10 years directing phases 1-4 clinical trials of antibiotics, oncology and intensive care products for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences; in these roles he was the principal involved in an IPO on UK’s main list, trade sales to international companies in Japan and the USA and significant fund raising rounds. He has been Chairman of Silence Therapeutics (AIM listed) and Chairman of Definigen Ltd, a private Cambridge University spinout. He is currently on the Board of three biotechnology companies; AzurRx Biotherapeutics, a New York based drug development company listed on NASDAQ; Cristal Therapeutics, a Netherlands based company specialising in nanoparticle medicines; and Skyline Vet Pharma, a US based private company repurposing human drugs for use in companion animals. He is also Chairman of the SWAHSN (South West Academic Health Science Network), which seeks to improve and sustain the healthcare provision in the south-west of England by linking innovation from industry, academia and the NHS. Dr Riddell is on the Remuneration committee.
Lindsay Melvin, Chief Financial Officer
Mr Melvin is a chartered accountant and brings 30 years of financial and business experience to Feedback. Most recently he was Chief Executive Officer of the Chartered Institute of Payroll Professionals (CIPP) for eight years until July 2016. CIPP was voted the UK’s best association in the 2016 Associations Excellence Awards and was also voted as one of the Sunday Times “Best 100 Not for Profit Organisations” in 2016. Previously, Mr Melvin held Director-level roles in small- to medium-sized public and private companies including Arthur Shaw & Co plc where he was Finance Director for six years. Mr Melvin started his career at Grant Thornton where he spent 11 years.
Tim Irish, Non-Executive Director
Tim is a Professor of Practice at Kings College London as well as a board member of Bournemouth University. Tim joined the board of the National Institute for Health and Care Excellence (NICE) in April 2015 and became the Senior Independent Director in May 2017. Tim has worked in the life sciences industry for thirty years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips the latter two in senior positions responsible for medical imaging. Tim also currently holds a number of non-executive positions in health and technology related entities.
Simon Sturge, Non-Executive Director
Mr Sturge joined Merck Healthcare in 2014 and is currently Chief Operating Officer and member of the Healthcare Executive Committee. He is an experienced healthcare executive in the UK and has built a very strong reputation not only in the biotechnology industry but also in the investment community. His experience includes eight years at Celltech, and he was the founder and CEO of RiboTargets which later reversed into Vernalis Plc. After serving as CEO of OctoPlus N.V. for two years, he became Senior Vice President of Boehringer Ingelheim’s Biopharmaceutical Business. Mr Sturge is a regular speaker at conferences including the World Economic Forum.
The Board recognises the importance of sound corporate governance and with that aim, the Company has adopted policies and procedures, which reflect the principles of the UK Corporate Governance Code, as published by the Financial Reporting Council’s Committee on Corporate Governance (commonly known as the “UK Corporate Governance Code”) and appropriate to the Company’s size. The Company does not fully comply with the UK Corporate Governance Code.
The Board meets monthly to review key operational issues and the strategic development of the Group. The financial performance of the Group is reported and monitored. All matters of a significant nature are discussed in the forum of a board meeting. The Board is responsible for internal controls to minimise the risk of financial or operational loss or material misstatement. The controls established are designed to meet the particular needs of the Company having regard to the nature of its business.
The Directors believe that the Board has sufficient experience in accounting systems and controls which will provide a reasonable basis for them to make proper judgements as to the financial position and prospects of the Group.
The Company also has established an Audit Committee and a Remuneration Committee with formally delegated duties and responsibilities.
The Remuneration Committee comprises Dr Alastair Riddell, Professor Tim Irish and Mr Simon Sturge and is responsible for the scale and structure of the remuneration of the Executive Directors. The recommendations of the committee must be approved by the Board of Directors before they can be approved. No director or manager shall be involved in decisions relating to his or her own remuneration.
The Audit Committee comprises Dr Alastair Riddell, Professor Tim Irish and Mr Simon Sturge and is required to monitor the integrity of the financial statements of the company, including the interim and annual reports. The committee also reviews financial returns to regulators and any financial information contained in announcements of a price sensitive nature. The committee shall also consider and make recommendations to the Board, to be put to shareholders for approval at the AGM, as to the appointment or re-appointment of the company’s external auditor and together with the external auditors, determines the scope of the audit.
The Audit Committee has unrestricted access to the Company’s auditors.
The Nomination Committee comprises Dr Alastair Riddell, Professor Tim Irish and Mr Simon Sturge and is responsible for selecting and appointing directors.
The Group will try to ensure, in accordance with Rule 21 of the AIM Rules, that the Board and applicable employees do not deal in any Ordinary Shares during a close period (as defined in the AIM Rules) and has adopted a code on dealings in the Company’s securities.
UK City Code on Takeovers and Mergers
The Company is subject to the UK City Code on Takeovers and Mergers.
Company registration number: 598696 Incorporated in England and Wales
Unit 5 Grange Park
Main country of operation is England.
KEY COMPANY ADVISORS
Nominated Advisor (NOMAD):
Allenby Capital Limited
5 St Helen’s place
Allenby Capital Limited
5 St Helen’s place
Peterhouse Corporate Finance Limited
New London House
15 Eldon Street
Share Registrars Ltd
17 West Street
26 Red Lion Square
The Company’s shares are traded solely on AIM.
As at 9th May 2018, the company had in issue 281,616,584 Ordinary Shares of 0.25 pence each. The Company did not hold any shares in Treasury.
As at 9th May 2018, shareholders who have notified the company of shareholdings in excess of 3% are:
|Shareholder||No. of Shares||%|
|T E Brown||11,689,111||4.15|
|T W G Charlton||69,437,408||24.66|
|W R Ruffler||12,597,893||4.47|
|University of Sussex||9,400,000||3.34|
|Jonathan David Selby Cranston||20,000,000||7.10|
Percentage of AIM securities not in public hands
As at 9th May 2018, the percentage of AIM securities not in public hands as defined by the AIM rules and insofar as the Company is aware is 34.14%.
Restrictions on the transfer of securities
There are no restrictions on the transfer of Feedback plc securities.
A List of constitutional and other documents can be found here